ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

antihemophilic factor, human recombinant

Also written as “Antihemophilic factor, recombinant, manufactured protein-free”, “Recombinant Factor VIII (BAY81-8973)” and “ADVATE”.

Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 3 companies.

Drug pageAntihemophilic factor, human recombinant: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 21, 200516 company-led studies, 1 open or runningNext primary completion: Nov 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only101 open or runningphase 4since Oct 21, 2005Sep 8, 2005Nov 25, 2027phase 3 · NCT07129343
Bayerits history only50 open or runningphase 4since Sep 4, 2020Dec 8, 2009none ahead
Novo Nordisk10 open or runningphase 1since Feb 4, 2009Feb 4, 2009none ahead

Also a collaborator on its studies: Takeda Development Center Americas and Baxter Innovations.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novo Nordisk only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 4, 2009First study: phase 1 study in Hemophilia AFirst studyNCT00837356 · 23 enrolled · Germany, Israel, Italy and more

TargetBeta

F8 →read by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule

Other programs on F8

ProgramCompanyFurthest phaseStudies
efanesoctocog alfaruleSanofiphase 412
omfiloctocog alfaruleSinocelltech Groupphase 46
lonoctocog alfaruleCSLphase 34

Studies

The one study Novo Nordisk leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00837356Hemophilia A · Germany, Israel, Italy and more1CompletedOct 200923

How it is read

Names in the registry

  • “Antihemophilic factor, recombinant, manufactured protein-free”, 8 entries
  • “Recombinant Factor VIII (BAY81-8973)”, 3 entries
  • “ADVATE”, 2 entries
  • “Recombinant Factor VIII (Kovaltry, BAY81-8973)”, 2 entries
  • “Antihemophilic Factor (Recombinant)”, 1 entry

Codes read as this program: BAY818973.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.